A re-view of cellular senescence: Friend or foe of tumorigenesis?;Une re-vue de la sénescence cellulaire: Ami ou ennemi de la promotion tumorale?

Medecine/Sciences

Volumn 25, Issue 2, 2009, Pages 153-160

  Bischof, Oliver ^a   Dejean, Anne ^a   Pineau, Pascal ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE; MAMMALIA;

EID: 60149108878     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2009252153     Document Type: Review

References (48)

1. Campisi J, D'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007 ; 8 : 729-40.
2. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008 ; 8 : 450-8.
3. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008 ; 20 : 150-5.
4. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006 ; 66 : 2881-4.
5. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004 ; 23 : 2919-33.
6. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007 ; 1775 : 5-20.
7. Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle 2005 ; 4 : 1722-4.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
9. Adams PD. Remodeling chromatin for senescence. Aging Cell 2007 ; 6 : 425-62.
10. Narita M. Cellular senescence and chromatin organisation. Br J Cancer 2007 ; 96 : 686-91.
11. Bischof O, Dejean A. SUMO is growing senescent. Cell Cycle 2007 ; 6 : 677-81.
12. Sedivy JM. Telomeres limit cancer growth by inducing senescence: long-sought in vivo evidence obtained. Cancer Cell 2007 ; 11 : 389-91.
13. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006 ; 444 : 638-42.
14. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006 ; 444 : 633-7.
15. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003 ; 13 : 1549-56.
16. Herbig U, Jobling WA, Chen BP, et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004 ; 14 : 501-13.
17. Reaper PM, di Fagagna F, Jackson SP. Activation of the DNA damage response by telomere attrition: a passage to cellular senescence. Cell Cycle 2004 ; 3 : 543-6.
18. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002 ; 21 : 4338-48.
19. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008 ; 10 : 361-9.
20. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005 ; 436 : 642.
21. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005 ; 436 : 725-30.
22. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005 ; 436 : 720-4.
23. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005 ; 436 : 660-5.
24. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007 ; 11 : 461-9.
25. Guo X, Deng Y, Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J 2007 ; 26 : 4709-19.
26. Londono-Vallejo A, Lenain C, Gilson E. Cibler les télomères pour forcer les cellules cancéreuses à rentrer en sénescence. Med Sci (Paris) 2008 ; 24 : 383-9.
27. Te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002 ; 62 : 1876-83.
28. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007 ; 445 : 656-60.
29. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007 ; 445 : 61-5.
30. Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008 ; 132 : 363-74.
31. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006 ; 8 : 877-84.
32. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008 ; 133 : 1019-31.
33. Acosta JC, O'Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008 ; 133 : 1006-18.
34. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999 ; 59 : 5002-11.
35. Krtolica A, Campisi J. Integrating epithelial cancer, aging stroma and cellular senescence. Adv Gerontol 2003 ; 11 : 109-16.
36. Liu D, Hornsby PJ. Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia 2007 ; 9 : 418-26.
37. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007 ; 67 : 3117-26.
38. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005 ; 120 : 513-22.
39. Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 2008 ; 98 : 245-9.
40. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003 ; 22 : 4212-22.
41. Sage J, Miller AL, Perez-Mancera PA, et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003 ; 424 : 223-8.
42. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006 ; 8 : 1291-7.
43. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR. Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 2006 ; 6 : 25.
44. Erenpreisa J, Cragg MS. Cancer: a matter of life cycle ? Cell Biol Int 2007 ; 31 : 1507-10.
45. Gire V. La sénescence : une barrière télomé rique à l'immortalité ou une réponse cellulaire aux stress physiologiques ? Med Sci (Paris) 2005 ; 21 : 491-7
46. Chien WW, Ffrench M. Régulation de p16INK4a, sénescence et oncogenèse. Med Sci (Paris) 2006 ; 22 : 865-71.
47. Toledo F, Bluteau O, Simeonova I. Réactivation de p53 dans les tumeurs : une stratégie antitumorale prometteuse. Med Sci (Paris) 2007 ; 23 : 565-7.
48. Gaumont-Leclerc MF, Ferbeyre G. Les cytokines préviennent les tumeurs via un mécanisme de sénescence cellulaire. Med Sci (Paris) 2009 ; 25 : 138-40.